ResMed Inc. 10-Q Summary: Period Ended December 31, 2007
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for ResMed Inc., a leading developer and manufacturer of medical equipment for sleep-disordered breathing and respiratory disorders. The report covers the three and six-month periods ended December 31, 2007. The company operates globally with manufacturing in Australia, France, and the U.S., and sales in over 68 countries.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2007 | Six Months Ended Dec 31, 2007 |
|---|---|---|
| Net Revenues | $202.7 million | $388.4 million |
| Gross Profit | $121.3 million | $233.1 million |
| Gross Margin | 59.9% | 60.0% |
| Net Income | $26.9 million | $51.0 million |
| Diluted EPS | $0.34 | $0.65 |
| Cash from Operations (6mo) | $47.0 million | |
| Total Debt (Current + Long-term) | $132.6 million | |
| Cash & Cash Equivalents | $278.5 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 14% ($24.3 million) for the quarter and 14% for the six-month period compared to the prior year. Growth was driven by increased unit sales of flow generators and masks, particularly new products like the Mirage Liberty and VPAP Adapt SV. International sales grew 21% (9% organic), aided by favorable currency movements.
- Margin Compression: Gross margin decreased to 59.9% (quarter) and 60.0% (six months) from 62.6% and 62.3% in the prior year periods. This was primarily due to reduced average selling prices, partially offset by a favorable product mix shift.
- Operating Expenses: Selling, general, and administrative (SG&A) expenses rose 18% due to increased personnel and currency impacts. Research and development (R&D) expenses increased 24% (quarter) and 22% (six months) due to new product development and headcount growth.
- Restructuring: The company incurred $2.3 million in restructuring expenses for the six-month period, related to streamlining European management and closing regional offices.
- Net Income: Despite revenue growth, net income decreased slightly to $26.9 million (quarter) and $51.0 million (six months) compared to $29.0 million and $54.0 million in the prior year periods, largely due to higher operating expenses and restructuring costs.
Outlook, Risks, and Unusual Items
- Product Recall: A voluntary recall of approximately 300,000 S8 flow generators initiated in April 2007 resulted in a total estimated cost of $59.7 million. As of December 31, 2007, a remaining liability of $7.4 million was accrued. Actual costs could differ from estimates.
- Real Estate Transaction: The company agreed to sell and leaseback its Poway, California headquarters for $25.3 million, expected to close in March 2008 with an estimated profit of $6.5 million.
- Capital Expenditures: Significant construction is underway for a new corporate headquarters in San Diego, with $18.2 million incurred to date and an estimated $87 million remaining. Funding is expected from cash on hand and an undrawn revolving credit facility.
- Foreign Currency Risk: The company faces exposure to exchange rate fluctuations, particularly with the Australian dollar and Euro. Hedging programs are in place, but currency movements significantly impacted reported revenues and expenses.
- Legal Proceedings: Ongoing litigation includes a German patent inventorship dispute and an Australian university lawsuit regarding intellectual property. Management does not expect these to have a material adverse effect.
Investor Verification Checklist
- Verify the remaining liability and potential cost revisions associated with the S8 product recall.
- Monitor the progress and final costs of the new San Diego corporate headquarters construction.
- Assess the impact of foreign currency fluctuations on future margins, given the significant international revenue base.
- Review the status of the European restructuring and its impact on future operating expenses.
- Confirm the closing details and financial impact of the Poway, California property sale-leaseback transaction.